A Phase I Trial of OXi4503 (a Vascular Disrupting Agent) given by 3 x weekly intravenous infusions to patients with advanced solid tumours.

Trial Profile

A Phase I Trial of OXi4503 (a Vascular Disrupting Agent) given by 3 x weekly intravenous infusions to patients with advanced solid tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Combretastatin A1 phosphate (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Mateon Therapeutics; OXiGENE
  • Most Recent Events

    • 11 Jan 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 11 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jul 2010 United Kingdom Clinical Research Network reports accrual to date changed from 105% to 112%.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top